235 related articles for article (PubMed ID: 22686619)
21. Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo.
Shimizu Y; Koyasu S; Suzukida M; Izumi K; Kidera E; Shindo T; Saga T; Ono M; Takaori-Kondo A; Nakamoto Y
Ann Nucl Med; 2022 Mar; 36(3):319-326. PubMed ID: 35034259
[TBL] [Abstract][Full Text] [Related]
22. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.
Zinzani PL; Karlin L; Radford J; Caballero D; Fields P; Chamuleau ME; d'Amore F; Haioun C; Thieblemont C; González-Barca E; García CG; Johnson PW; van Imhoff GW; Ng T; Dwyer K; Morschhauser F
Haematologica; 2016 Oct; 101(10):e407-e410. PubMed ID: 27418646
[No Abstract] [Full Text] [Related]
23. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
Duvic M; Pinter-Brown LC; Foss FM; Sokol L; Jorgensen JL; Challagundla P; Dwyer KM; Zhang X; Kurman MR; Ballerini R; Liu L; Kim YH
Blood; 2015 Mar; 125(12):1883-9. PubMed ID: 25605368
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
[TBL] [Abstract][Full Text] [Related]
25. Persistent complete remission of acute leukemic-phase CCR4-positive gamma-delta peripheral T-cell lymphoma by autologous stem cell transplantation with mogamulizumab.
Furukawa M; Ikeda K; Ohkawara H; Saito S; Takahashi H; Ueda K; Matsumoto H; Hashimoto Y; Ohto H; Ogawa K; Takeishi Y
Int J Hematol; 2015 Oct; 102(4):498-505. PubMed ID: 25975265
[TBL] [Abstract][Full Text] [Related]
26. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
[TBL] [Abstract][Full Text] [Related]
27. Antibody therapy for Adult T-cell leukemia-lymphoma.
Ishida T; Ueda R
Int J Hematol; 2011 Nov; 94(5):443-52. PubMed ID: 21993874
[TBL] [Abstract][Full Text] [Related]
28. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.
Ishida T; Utsunomiya A; Jo T; Yamamoto K; Kato K; Yoshida S; Takemoto S; Suzushima H; Kobayashi Y; Imaizumi Y; Yoshimura K; Kawamura K; Takahashi T; Tobinai K; Ueda R
Cancer Sci; 2017 Oct; 108(10):2022-2029. PubMed ID: 28776876
[TBL] [Abstract][Full Text] [Related]
29. CCR4 and its ligands: from bench to bedside.
Yoshie O; Matsushima K
Int Immunol; 2015 Jan; 27(1):11-20. PubMed ID: 25087232
[TBL] [Abstract][Full Text] [Related]
30. Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab.
Ishitsuka K; Murahashi M; Katsuya H; Mogi A; Masaki M; Kawai C; Goto T; Ishizu M; Ikari Y; Takamatsu Y; Ishibashi H; Nimura S; Takeshita M; Tamura K
Int J Hematol; 2015 Oct; 102(4):493-7. PubMed ID: 25995001
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma.
Fujii K; Sakamoto Y; Masaki A; Murase T; Tashiro Y; Yonekura K; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Ishida T; Inagaki H
J Pathol Clin Res; 2021 Jan; 7(1):52-60. PubMed ID: 33022137
[TBL] [Abstract][Full Text] [Related]
32. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
Beygi S; Duran GE; Fernandez-Pol S; Rook AH; Kim YH; Khodadoust MS
Blood; 2022 Jun; 139(26):3732-3736. PubMed ID: 35436328
[TBL] [Abstract][Full Text] [Related]
33. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
Shiratori S; Ohhigashi H; Ito S; Kudo K; Adachi M; Minamimoto T; Kato J; Osai Y; Tsutsumi Y; Teshima T
Hematol Oncol; 2017 Mar; 35(1):138-140. PubMed ID: 26177633
[No Abstract] [Full Text] [Related]
34. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation.
Motohashi K; Suzuki T; Kishimoto K; Numata A; Nakajima Y; Tachibana T; Ohshima R; Kuwabara H; Tanaka M; Tomita N; Ishigatsubo Y; Fujisawa S
Int J Hematol; 2013 Aug; 98(2):258-60. PubMed ID: 23801427
[TBL] [Abstract][Full Text] [Related]
36. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
Mukai M; Maeda H; Narushima K; Mould DR; Greene D
J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
[TBL] [Abstract][Full Text] [Related]
37. Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.
Sato T; Coler-Reilly ALG; Yagishita N; Araya N; Inoue E; Furuta R; Watanabe T; Uchimaru K; Matsuoka M; Matsumoto N; Hasegawa Y; Yamano Y
N Engl J Med; 2018 Feb; 378(6):529-538. PubMed ID: 29414279
[TBL] [Abstract][Full Text] [Related]
38. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
Tanaka H; Fujiwara H; Ochi F; Tanimoto K; Casey N; Okamoto S; Mineno J; Kuzushima K; Shiku H; Sugiyama T; Barrett AJ; Yasukawa M
Clin Cancer Res; 2016 Sep; 22(17):4405-16. PubMed ID: 27091408
[TBL] [Abstract][Full Text] [Related]
39. Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T-cell leukaemia-lymphoma.
Ohno N; Kobayashi S; Ishigaki T; Yuji K; Kobayashi M; Sato K; Watanabe N; Tojo A; Uchimaru K
Br J Haematol; 2013 Dec; 163(5):683-5. PubMed ID: 23998261
[No Abstract] [Full Text] [Related]
40. Cutaneous adverse reaction of mogamulizumab, an anti-CC chemokine receptor 4 monoclonal antibody: Shared histopathological features with thymoma-associated multi-organ autoimmunity.
Kanno K; Honma M; Ishida-Yamamoto A
J Dermatol; 2017 Jun; 44(6):e117-e118. PubMed ID: 28026038
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]